French nuclear medicine giant Curium acquires Turkish Eczacibasi’s Monrol
Exterior view of Monrol’s manufacturing facility in Bulgaria, accessed on Apr. 1, 2025. (Photo via monrol.com)
French nuclear medicine leader Curium Pharma agreed to acquire Monrol, a nuclear medicine subsidiary of Turkish pharmaceutical giant Eczacibasi, as part of its strategy to expand its global manufacturing capabilities.
According to a company statement released on March 28, the acquisition aims to bolster Curium’s production capacity of Lutetium-177, a key radioisotope used in developing treatments for prostate and neuroendocrine cancers.
“Monrol’s manufacturing and logistics infrastructure in Istanbul, Türkiye, immediately adds scale to Curium’s vertically integrated production and distribution capabilities,” the statement said.
Curium CEO Chaitanya Tatineni described the investment as a step toward creating new opportunities to expand the company’s portfolio of life-changing diagnostic and therapeutic solutions for patients worldwide.
“We are delighted to welcome nearly 400 highly skilled and dedicated new colleagues to the Curium Group,” Tatineni added.
Eczacibasi Pharmaceutical and Industrial Investment CEO Emin Fadillioglu expressed pride in Monrol’s achievements and growth in recent years.
“This is a strong reflection of the business‘s quality, and we believe it will continue to thrive under Curium’s ownership, benefiting from greater access to advanced technologies and an extensive global network,” he said.
Founded in 2008, Monrol operates 13 facilities and exports to over 70 countries. With around 300 employees, it is one of the world’s leading producers of Lutetium-177.
